Phase I Study of the Combination of Vemurafenib, Carboplatin, and Paclitaxel in Patients with BRAF-Mutated Melanoma and Other Advanced Malignancies

BACKGROUND: BRAF inhibitors are effective against selected BRAF(V600)-mutated tumors. Preclinical data suggest that BRAF inhibition in conjunction with chemotherapy has increased therapeutic activity. METHODS: Patients with advanced cancers and BRAF mutations were enrolled to the dose-escalation stu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Bhatty, Minny, Kato, Shumei, Piha-Paul, Sarina A., Naing, Aung, Subbiah, Vivek, Huang, Helen J., Karp, Daniel D., Tsimberidou, Apostolia M., Zinner, Ralph G., Hwu, Wen-Jen, Javle, Milind, Patel, Sapna P., Hu, Mimi I., Varadhachary, Gauri R., Conley, Anthony P., Ramzanali, Nishma M., Holley, Veronica R., Kurzrock, Razelle, Meric-Bernstam, Funda, Chae, Young Kwang, Kim, Kevin B., Falchook, Gerald S., Janku, Filip
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6340722/
https://ncbi.nlm.nih.gov/pubmed/30383888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31812
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados